ViiV expands license to produce generic Apretude in low-income countries

4 hours ago 1
GlaxoSmithKline Headquarters In Brentford, London

Leon Neal

  • ViiV Healthcare, which is majority owned by GSK (NYSE:GSK), said it will expand a licensing agreement with the Medicines Patent Pool that will allow manufacturers to produce generic Apretude (cabotegravir) for low-income countries as a long-acting HIV treatment.
  • Previously, the agreement

Recommended For You

More Trending News

Read Entire Article